Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06568601 · ClinicalTrials.gov registry record · NA
Pharmacogenomic Informed Statin Prescribing
A NA study of Hypercholesterolemia, sponsored by VA Office of Research and Development.
- Recruiting
- Registry status
- NA
- Development phase
- 410
- Enrollment target
- 2
- Study locations
NCT06568601: Recruiting NA study of Hypercholesterolemia, sponsored by VA Office of Research and Development.
NCT06568601 is a NA study of Hypercholesterolemia that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 410 participants, below the 810-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (49% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06568601, a NA study of Hypercholesterolemia, is actively recruiting participants, sponsored by VA Office of Research and Development.
- RECRUITING
- Registry status
- NA
- Development phase
- 410 participants
- Enrollment target
- 2
- Study locations
Study Summary
Statins are the most cost-effective medications to lower cholesterol and cardiovascular disease (CVD) risk. However, many patients at high-risk for CVD do not accept or adhere to statins. This gap in patient's use of statins limits the full impact of these effective medications resulting in higher cholesterol levels and CVD risk. The main barriers to using statins are patients' perceived lack of benefit, excess risk of statin toxicity as well as their misperceptions of their CVD risk. Statin pharmacogenomic testing - an application of precision medicine - is a readily available, feasible, and inexpensive intervention that addresses this barrier by using genetic testing to identify the nearly 1 out of 2 patients with enhanced benefit and/or reduced risk of statin toxicity or increased risk for CVD. By communicating statin pharmacogenomic test results to Veterans at high-risk for CVD not taking statin therapy, the investigators aim to improve patients' perceptions of their risk of CVD and statins and, in turn, their acceptance of and adherence to statins to reduce their cholesterol levels and CVD risk.
Primary Outcome
The primary effectiveness outcome will be the change in LDL-cholesterol level from baseline to 15-months.
Conditions Studied
Interventions
- GENETIC Pharmacogenetic and polygenic risk testing
- OTHER Active control
Study Locations (2)
Indiana
- Richard L. Roudebush VA Medical Center, Indianapolis, IN - Indianapolis
North Carolina
- Durham VA Medical Center, Durham, NC - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 410 participants |
| Start Date | 2025-04-01 |
| Est. Completion | 2028-07-28 |
| Phase | NA |
What NCT06568601 shows while recruiting
NCT06568601 is an interventional study that assigns participants to a tested intervention. The registered 410 participants enrollment target is mid-sized for trials with a published cap, below the 810-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (49% lower).
The record links to 1 condition, with Hypercholesterolemia appearing as the primary indexed condition, and to 2 interventions - of which Pharmacogenetic and polygenic risk testing is the first listed.
NCT06568601 reports a single indexed study location in Indiana, North Carolina.
Frequently Asked Questions
What is clinical trial NCT06568601 about?
NCT06568601 is a clinical study titled "Pharmacogenomic Informed Statin Prescribing". Statins are the most cost-effective medications to lower cholesterol and cardiovascular disease (CVD) risk. However, many patients at high-risk for CVD do not accept or adhere to statins. This gap in patient's use of statins limits the full impact of these effective medications resulting in higher c...
What is the current status of trial NCT06568601?
This trial is currently recruiting. It is a NA study. The enrollment target is 410 participants. The study started on 2025-04-01. Estimated completion is 2028-07-28.
What conditions does trial NCT06568601 study?
This clinical trial studies the following conditions: Hypercholesterolemia.
What interventions are being tested in trial NCT06568601?
The interventions under investigation include: Pharmacogenetic and polygenic risk testing (GENETIC), Active control (OTHER).
Who is sponsoring clinical trial NCT06568601?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06568601 being conducted?
This trial has 2 study locations across Indiana, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypercholesterolemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06568601's enrollment target sits among peer trials
410 21st of 62 higher than 42 of 62 other Hypercholesterolemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypercholesterolemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Church-based Health Intervention to Eliminate Racial Inequalities in Cardiovascular Health
RECRUITING · NA
-
A Tool to Help Patients With Muscle Symptoms After Taking a Statin Medication.
ACTIVE NOT RECRUITING · NA
-
Effect of Diabetes Mellitus on Cholesterol Metabolism
COMPLETED · NA
-
Evaluating the Efficacy of Pediatric Lipid Screening Alerts
COMPLETED · NA
-
Niacin for Treatment of Elevated Cholesterol and Triglycerides in HIV-Infected Patients
COMPLETED · NA
-
Diets Enriched With Pecans
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02043691 · 410 participants · NA
Evaluation of the Cook Custom Aortic Endograft, the Zenith t-Branch Endovascular Graft, and Surgeon-Modified Endograft in Treating Aortic Pathologies
- NCT03042975 · 410 participants
Imaging Genetics of Laryngeal Dystonia
- NCT05730036 · 410 participants · Phase 3
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
- NCT05751473 · 410 participants · NA
Reducing Posttraumatic Stress Disorder (PTSD) Symptoms in First Responders and Frontline Health Care Workers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI